(PharmaNewsWire.Com, July 15, 2017 ) Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which codes for the CFTR protein. As a multisystem condition, CF patients show great heterogeneity in presenting clinical symptoms. CF mainly affects the respiratory and gastrointestinal tracts. Three classes of drugs have been used to for treatment in CF patients: inhaled antibiotics for bacterial and fungal respiratory infections, mucolytic drugs for mucociliary clearance of the airways, and pancreatic enzyme replacement therapies (PERTs) for treatment of CF induced exocrine pancreatic insufficiency (EPI) . During the last five years, a new class of drugs was launched into the market, specifically treating the underlying cause of CF. These CFTR modulators help restore function of the insufficient CFTR protein. Publisher projects the global cystic fibrosis marketplace to experience tremendous growth during the forecast period. This growth will be driven primarily by the highly anticipated arrival of the CFTR modulator, Vertex Pharmaceuticals' ivacaftor/tezacaftor. Insmed's inhaled antibiotic Arikace (liposomal amikacin) is also expected to launch during the forecast period but is not expected to drive CF market growth as much as the CFTR modulator, since it will be competing with other inhaled antibiotics.
- Overview of cystic fibrosis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. - Annualized CF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CF therapeutics market. - Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. - Analysis of the current and future market competition in the global CF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy The report will enable you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list. - Develop business strategies by understanding the trends shaping and driving the global CF therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CF therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track drug sales in the global CF therapeutics market from 2015-2025. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Companies Mentioned: AbbVie Chiesis USA Forest Laboratories Gilead Insmed Therapeutics Johnson & Johnson Novartis Pharmaxis Raptor Pharmaceuticals Roche Vertex Pharmaceuticals Inquire for Report at http://www.reportsweb.com/inquiry&RW0001851104/buying
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
